Status:
COMPLETED
Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease
Lead Sponsor:
Danish Research Centre for Magnetic Resonance
Collaborating Sponsors:
University Hospital Bispebjerg and Frederiksberg
Danish Movement Disorder Society (DANMODIS)
Conditions:
Dyskinesia, Drug-Induced
Parkinson Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Using a within-subject cross-over design, we will include 20 patients with Parkinson disease (PD) and peak-of-dose dyskinesia. Patients will be studied after withdrawal from their normal dopaminergic...
Detailed Description
The most common form of levodopa-induced dyskinesias (LID) manifests when levodopa levels are highest and is referred to as peak-of-dose dyskinesia. 50% of patients experience LID after 4-6 years of t...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Parkinson's Disease (Hoehn \& Yahr 1-3)
- Peak-of-dose levodopa-induced dyskinesia
Exclusion
- Insufficient Danish language skills
- Neurological disease other than Parkinson's Disease
- Major psychiatric illness
- Sedatives or serotonergic medication in their current treatment.
- Severe tremor
- Montreal Cognitive Assessment score \< 26
- Contraindication for transcranial magnetic stimulation:
- Epilepsy or epilepsy in 1st degree relatives
- Contraindications for MRI-scanning:
- Pacemaker
- Pregnancy
- Metallic foreign objects inside the body
- Severe claustrophobia
Key Trial Info
Start Date :
August 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 16 2018
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03354455
Start Date
August 1 2017
End Date
September 16 2018
Last Update
August 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Danish Research Centre for Magnetic Resonance
Hvidovre, Capital Region, Denmark, 2650